XXX療法的意義在于打破傳統(tǒng)的治療選擇，實(shí)現(xiàn)大分子和小分子產(chǎn)品的開發(fā)和商業(yè)化。目前領(lǐng)導(dǎo)者們?nèi)栽谂鉀Q的難題包括：內(nèi)部開發(fā)團(tuán)隊(duì)組建或是利用外包服務(wù)，對(duì)開發(fā)生產(chǎn)采用集中或是分散管理，以及是否將資本投入到市場上前所未有的產(chǎn)品中。
The meaning of XXX therapies lies in breaking the traditional treatment options to realize the development and commercialization of macromolecular and micromolecular products. Currently, leaders are trying to tackle the following challenges, including setting up an internal development team or outsourcing this function; centralized or decentralized management for development and production, and whether to invest capital in unprecedented products on the market.
XXX企業(yè)參與了從上游到下游的自上而下且錯(cuò)綜復(fù)雜的產(chǎn)品流程，包含產(chǎn)品的原物料搜集到產(chǎn)品追蹤，一直到XXX產(chǎn)品安全地送達(dá)到患者手上。因此，領(lǐng)導(dǎo)者們也正致力于尋找一個(gè)協(xié)調(diào)良好且同步所有功能的價(jià)值鏈。
XXX enterprises have participated in the top-down and intricate product flows from the upstream to the downstream parts, spanning from the gathering of raw materials and product tracking to the safe delivery of XXX products to patients. Therefore, leaders are also committed to seeking a well-coordinated value chain that can synchronize all functions.
產(chǎn)業(yè)鏈中各環(huán)節(jié)的領(lǐng)導(dǎo)者們都強(qiáng)調(diào)XXX企業(yè)的靈活性、風(fēng)險(xiǎn)承受和快速?zèng)Q策能力的重要性，部分大型生物藥企在并購或收購XXX企業(yè)的時(shí)候，都選擇進(jìn)行圍欄策略以維持運(yùn)行和一定程度的自主權(quán)。
Leaders in all parts of the industrial chain emphasize the importance of the flexibility, risk tolerance and rapid decision-making capacity of XXX enterprises. When merging or acquiring XXX companies, most leading bio-pharmaceutical companies choose to use the ring fence strategy to maintain operation and a certain extent of autonomous right.